Canada Ovarian Cancer Diagnostics Market

Canada Ovarian Cancer Diagnostics Market Insights Forecasts to 2035

• The Canada Ovarian Cancer Diagnostics Market Size was estimated at USD 63.44 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.78% from 2025 to 2035
• The Canada Ovarian Cancer Diagnostics Market Size is Expected to Reach USD 117.75 Million by 2035

According to a research report published by Decisions Advisors, The Canada Ovarian Cancer Diagnostics Market Size is Anticipated to Reach USD 117.75 Million by 2035, Growing at a CAGR of 5.78% from 2025 to 2035. The Canadian ovarian cancer diagnostics market is growing because older women are receiving cancer diagnoses, more individuals are becoming aware of the importance of preventive detection of cancer, biomarker-based diagnostics are obtaining stronger and increasing funds are being given to cancer research by both the government and private companies.

Market Overview

The subsection of the Canadian healthcare and biotechnology industry that produces, provides, and distributes diagnostic tools, equipment, and amenities targeted at the early detection, precise diagnosis, and monitoring of ovarian cancer patients is referred to as the ovarian cancer diagnostics market. This is process of determining and verifying the existence of ovarian cancer in individuals who are suspected of possessing the disease is known as ovarian cancer diagnostics. Many kinds of examinations, tests, and imaging technologies are performed in ovarian cancer diagnostic procedures to look for tumours or cancerous cells in the ovaries or tissue surrounding them. In addition, novel biomarkers, imaging techniques, and diagnostic tools are being found as the outcome of ongoing research and development efforts across all areas of oncology, including ovarian cancer. Better patient outcomes and earlier detection of ovarian cancer are made possible by this ongoing innovation, which improves the sensitivity, specificity, and accuracy of cancer diagnostics.

It has the lowest 3-year net survival rate in Canada for advanced cases. Ovarian cancer remains a significant health concern, with an estimated 2,000 deaths and 3,100 new cases expected in 2025. Women between the ages of 55 and 64 are reported to have the highest incidence.

The "Bridging the Gap for Ovarian Cancer Treatments Grants Competition," which was jointly launched by Ovarian Cancer Canada (OCC) and the Cancer Research Society (CRS), offers up to $1.2 million for clinical and translational research projects centred on precision oncology in ovarian cancer.

Through OCC and CRS, Manitoba announced a $1 million investment over three years to support both clinical and discovery research on ovarian cancer.

Report Coverage

This research report categorises the market for the Canada ovarian cancer diagnostics market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada ovarian cancer diagnostics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada ovarian cancer diagnostics market.

Driving Factors

The market for ovarian cancer diagnostics in Canada is being propelled by multiple important factors. Ovarian cancer is growing more common, especially in older populations, which is driving up demand for early and precise detection techniques. Liquid biopsy, next-generation sequencing, and advanced imaging are examples of novel technological developments that are increasing the speed and accuracy of diagnosis, allowing market expansion through them. Further, innovation and accessibility are also being accelerated by government support for cancer research and early screening programs, which boost the market dynamics. Besides, genetic testing and biomarker-based diagnostics are also becoming popular due to the push for precision medicine and expanding public awareness campaigns.

Grants for translational and clinical research are still available from the Gynecologic Cancer Initiative and other foundations; recent competitions have awarded up to $175,000 for significant projects.

Restraining Factors

The primary barriers to the ovarian cancer diagnostics market in Canada are high costs, regulatory delays, a lack of standardised screening, awareness gaps, and uneven infrastructure.

Market Segmentation

The Canada ovarian cancer diagnostics market share is classified into cancer and diagnosis.

• The epithelial tumour segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.

The Canada ovarian cancer diagnostics market is segmented by cancer into epithelial tumour, germ cell tumour, stromal cell tumour, and others. Among these, the epithelial tumour segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. This is due to a high number of patients who have this type of cancer. As a result, there is a greater need for diagnostic instruments and procedures designed especially to identify epithelial tumours with the efficiency and accuracy of detecting epithelial ovarian tumours.

• The imaging segment held a significant share in 2024 and is projected to grow at a rapid pace over the forecast period.

The Canada ovarian cancer diagnostics market is divided by diagnosis into imaging, blood test, biopsy, and others. Among these, the imaging segment held a significant share in 2024 and is projected to grow at a rapid pace over the forecast period. Ovarian cancer diagnostics still rely heavily on imaging, which is changing quickly and has a direct influence on the market growth. The first-line modality is still ultrasound, especially transvaginal sonography, due to its affordability and accessibility this segment impact still high. Moreover, its consistency, accuracy, and clinical confidence are increasing with the use of structured reporting systems like O-RADS for MRI and ultrasound.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada ovarian cancer diagnostics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Ovarian Cancer Canada
• Cleo Diagnostics Ltd
• AOA Dx
• Princess Margaret Cancer Centre (UHN)
• BC Cancer Agency
• Sunnybrook Health Sciences Centre
• McGill University Health Centre (MUHC)
• Others

Recent Developments:

• In November 2025, the mDETECT blood test, designed to identify DNA changes linked to ovarian cancer, is moving into its next phase of development in Canada following a major investment from Ovarian Cancer Canada (OCC). This funding is helping transition the test from laboratory research into real-world clinical application.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Canada ovarian cancer diagnostics market based on the below-mentioned segments:

Canada Ovarian Cancer Diagnostics Market, By Cancer

• Epithelial Tumour
• Germ Cell Tumour
• Stromal Cell Tumour
• Others

Canada Ovarian Cancer Diagnostics Market, By Diagnosis

• Imaging
• Blood Test
• Biopsy
• Others